-
Acura Pharmaceuticals Inc. (NASDAQ:ACUR), Palatine, Ill. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Neurology, Drug delivery Acura said Pfizer launched Oxecta oxycodone tablets in the U.S. to manage acute and …
Published on 1/30/2012
-
BioReference Laboratories Inc. (NASDAQ:BRLI), Elmwood Park, N.J. Business: Pharmacogenetics BioReference launched OnkoMatch solid tumor genotyping test in the U.S. to identify genetic mutations as an aid to determine …
Published on 1/30/2012
-
Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506), Osaka, Japan GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Neurology The companies will co-market GlaxoSmithKline's 12.5 and 25 mg Paxil CR …
Published on 1/30/2012
-
Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Business: Cancer Eisai launched Halaven eribulin mesylate in Italy to treat locally advanced or metastatic breast cancer in patients who have previously received at …
Published on 1/30/2012
-
MediGene AG (Xetra:MDG), Martinsried, Germany Eczacibasi Group, Istanbul, Turkey Business: Infectious MediGene granted Eczacibasi's EIP Eczacibasi Ilac Pazarlama A/S subsidiary exclusive rights to commercialize genital …
Published on 1/30/2012
-
Pernix Therapeutics Holdings Inc. (NYSE-A:PTX), Magnolia, Texas Business: Gastrointestinal Pernix gained exclusive, U.S. marketing rights to an undisclosed gastroenterology product recently approved by FDA from an …
Published on 1/30/2012
-
Precision Therapeutics Inc., Pittsburgh, Pa. Business: Pharmacogenetics Precision expanded its BioSpeciFx tumor profiler for personalized cancer treatments to include a total of 21 biomarkers. The product is a selected …
Published on 1/30/2012
-
Veracyte Inc., South San Francisco, Calif. Sanofi (Euronext:SAN; NSYE:SNY), Paris, France Business: Diagnostic Veracyte granted Sanofi's Genzyme Corp. subsidiary exclusive, worldwide co-commercialization rights to …
Published on 1/30/2012
-
Antares Pharma Inc. (NYSE-A:AIS), Ewing, N.J. Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Business: Genitourinary Antares granted Daewoong exclusive rights to market oxybutynin gel 3% in South Korea. …
Published on 1/23/2012
-
Asahi Kasei Pharma Corp., Tokyo, Japan Dong-A Pharmaceutical Co. Ltd. (KSE:000640), Seoul, South Korea Business: Genitourinary Dong-A launched Asahi Kasei's Flivas naftopidil in Korea to treat benign prostatic …
Published on 1/23/2012
-
Fujirebio Inc., Tokyo, Japan Laboratory Corp. of American Holdings (NYSE:LH), Burlington, N.C. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Diagnostic LabCorp launched the Risk of Ovarian Malignancy …
Published on 1/23/2012
-
Glycobiosciences Inc., Georgetown, Ontario Hi-Tech Pharmacal Co. Inc. (NASDAQ:HITK), Amityville, N.Y. Business: Dermatology Glycobiosciences granted Hi-Tech exclusive, U.S. commercialization rights to a hyaluronic acid …
Published on 1/23/2012
-
Ind-Swift Ltd., Chandigarh, India Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Roche's Roche Diagnostics India Pvt. Ltd. granted Ind-Swift Indian commercialization rights to point-of-care …
Published on 1/23/2012
-
Insmed Inc. (NASDAQ:INSM), Monmouth Junction, N.J. Business: Neurology Insmed said its inventory for amyotrophic lateral sclerosis (ALS) drug iPlex mecasermin rinfibate is fully depleted. The company said about 10 …
Published on 1/23/2012
-
H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Neurology Lundbeck launched Sycrest asenapine in the U.K. to treat moderate to severe manic episodes …
Published on 1/23/2012
-
Melmed Holdings AG, Zug, Switzerland Uluru Inc. (NYSE-A:ULU), Addison, Texas Business: Dermatology Uluru finalized a deal granting Melmed's Altrazeal Trading Ltd. subsidiary exclusive rights to commercialize Altrazeal …
Published on 1/23/2012
-
MolecularHealth AG, New York, N.Y. Business: Bioinformatics MolecularHealth launched drug safety assessment and prediction tool Molecular Analysis of Side Effects (MASE). The MASE system combines adverse event …
Published on 1/23/2012
-
NextGen Group plc (LSE:NGG), Huntingdon, U.K. Business: Diagnostic NextGen's NextGen Sciences Inc. subsidiary launched its csfdiscovery82 cerebrospinal fluid (CSF) multiplex assay worldwide to discover and qualify 82 …
Published on 1/23/2012
-
Norgine B.V., Amsterdam, the Netherlands Applied Pharma Research S.A., Balerna, Switzerland Business: Gastrointestinal Applied Pharma Research granted Norgine commercialization rights to Setofilm ondansetron in Europe …
Published on 1/23/2012
-
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Endocrine/Metabolic Novartis launched Galvus vildagliptin in China as an add-on to metformin to treat Type II diabetes. The wholesale acquisition cost for a…
Published on 1/23/2012
-
Nuron Biotech Inc., Exton, Pa. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Business: Infectious Nuron granted Mitsubishi Tanabe exclusive rights to commercialize HibTITER Haemophilus influenzae…
Published on 1/23/2012
-
Apricus Biosciences Inc. (NASDAQ:APRI), San Diego, Calif. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Genitourinary Apricus granted Abbott exclusive, Canadian rights to commercialize erectile dysfunction…
Published on 1/16/2012
-
Apricus Biosciences Inc. (NASDAQ:APRI), San Diego, Calif. Elis Pharmaceuticals Ltd., Dubai, UAE Business: Infectious, Drug delivery Apricus granted Elis exclusive, commercialization rights to MycoVa in Saudi Arabia, …
Published on 1/16/2012
-
Aptalis Pharma Inc., Mont-Saint-Hilaire, Quebec Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Business: Neurology Kyowa's ProStrakan Group plc subsidiary granted Aptalis exclusive, U.S. commercialization rights …
Published on 1/16/2012
-
BL&H Co. Ltd., Seoul, Korea Cardium Therapeutics Inc. (NYSE-A:CXM), San Diego, Calif. Business: Dermatology Cardium granted BL&H Korean commercialization rights to Excellagen. Cardium will manufacture and supply the …
Published on 1/16/2012